Oncotarget最新文献

{"title":"Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report.","authors":"Cameron B Speyer, Kyle D Klingbeil, Manando Nakasaki, Sarah M Dry, Arun S Singh, Karo K Arzoo, Fritz C Eilber, Joseph G Crompton","doi":"10.18632/oncotarget.28863","DOIUrl":"https://doi.org/10.18632/oncotarget.28863","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Speyer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Gastrointestinal stromal tumors (GISTs) are molecularly defined by oncogenic alterations that predict clinical behavior and response to therapy. Activating mutations in KIT or PDGFRA characterize most GISTs and confer sensitivity to imatinib, whereas succinate dehydrogenase (SDH)&#x2013;deficient GISTs lack these mutations and are typically imatinib resistant. These molecular subtypes are generally considered mutually exclusive. We report a rare case of a small bowel GIST harboring both a somatic KIT exon 9 A502_Y503 duplication and a germline inactivating SDHC mutation (p.R50C). The patient received neoadjuvant high-dose imatinib with a marked radiographic and metabolic response, followed by complete surgical resection. Pathology demonstrated spindle cell GIST with significant treatment effect and retained SDHB expression. This case suggests that oncogenic KIT signaling may remain the dominant driver of GIST behavior despite the presence of a germline SDHC mutation and highlights the importance of integrated molecular interpretation in GIST management.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"226-231"},"PeriodicalIF":0.0,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023.","authors":"Navkirat Kahlon, Nahush Bansal, Sujatha Baddam, Jaisingh Rajput, Zaheer Qureshi","doi":"10.18632/oncotarget.28877","DOIUrl":"https://doi.org/10.18632/oncotarget.28877","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Kahlon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Multiple myeloma (MM), the second most common hematologic malignancy in the United States, has undergone transformative therapeutic innovation over the past five decades. Using SEER data from 1975 to 2023, we conducted a retrospective cross-sectional analysis to evaluate MM-specific mortality trends in relation to major treatment milestones. Age-adjusted mortality rates and Annual Percent Change (APC) were estimated using Joinpoint regression. Mortality increased from 1975 to 1994 (APC: 1.43%; P &lt; .01), declined modestly from 1994 to 2002 (&#x2013;0.70%; P = .02), dropped steeply from 2002 to 2009 (&#x2013;1.85%; P &lt; .01), plateaued between 2009 and 2014 (0.52%; P = .10), resumed decline from 2014 to 2021 (&#x2013;1.73%; P &lt; .01), and sharply decreased from 2021 to 2023 (&#x2013;5.64%; P &lt; .01). These inflection points align with the introduction of stem cell transplantation, proteasome inhibitors, immunomodulatory drugs, and next-generation immunotherapies including CAR T-cell therapy and bispecific antibodies. While these advances have improved survival, they also introduced chronic treatment burdens and rising costs. Our findings highlight the real-world impact of targeted therapies on population-level outcomes and underscore the urgent need for care models that ensure accessibility, affordability, and long-term sustainability in the era of precision oncology.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"216-225"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncotarget: Past, Present and Future: Trends in the publishing industry.","authors":"","doi":"10.18632/oncotarget.28852","DOIUrl":"10.18632/oncotarget.28852","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"173-177"},"PeriodicalIF":0.0,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13065247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials.","authors":"Maryam Aleid, Fatimah Aleid, Daniah Allbdi, Ahmad Rchdeih, Dhai Almuteri, Abdulelah Almesned, Samaa Alotab, Yumna AlMishary, Galia Alsamman, Atlal Abusanad","doi":"10.18632/oncotarget.28855","DOIUrl":"10.18632/oncotarget.28855","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Aleid et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Background/objectives: </strong>Programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are widely used in cancer treatment. Their benefit as adjuvant therapy in solid tumors is still being defined. This systematic review and meta-analysis evaluated the efficacy and safety of PD-1 and PD-L1 inhibitors as adjuvant treatment in patients with solid tumors.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of randomized controlled trials in accordance with PRISMA recommendations and PROSPERO registration CRD42024563699. PubMed, Web of Science, Cochrane Library, and Google Scholar were searched for randomized controlled trials published in English that evaluated adjuvant PD-1 or PD-L1 inhibitors in solid cancers.</p><p><strong>Results: </strong>Thirteen randomized controlled trials published between 2021 and 2023 were included. Adjuvant PD-1 and PD-L1 inhibitors improved disease-free survival (hazard ratio 0.75; 95% CI 0.65&#x2013;0.86) and distant metastasis-free survival (hazard ratio 0.69; 95% CI 0.54&#x2013;0.87). No clear difference in overall survival was observed. Trial-level subgroup sizes varied across cancer types.</p><p><strong>Conclusions: </strong>Adjuvant PD-1 and PD-L1 inhibitors improve disease-free and distant metastasis-free survival in selected patients with high-risk solid tumors. The clinical benefit must be balanced against higher toxicity rates. Because the number of studies within each cancer type remains limited, the strength of cancer-specific conclusions is restricted, and further research is required.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"120-135"},"PeriodicalIF":0.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer without borders: Policy frameworks for oncology care in humanitarian and conflict settings.","authors":"Pragnesh Parmar, Gunvanti Rathod","doi":"10.18632/oncotarget.28856","DOIUrl":"10.18632/oncotarget.28856","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Parmar and Rathod. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Cancer is an escalating yet neglected health crisis among refugees, migrants, and populations affected by conflict. Despite increasing global focus on non-communicable diseases (NCDs), oncology remains largely absent from humanitarian health agendas. This narrative review synthesizes evidence from peer-reviewed literature, humanitarian agency reports, and case studies from Gaza, Sudan, and Ukraine to examine the policy, ethical, and clinical dimensions of oncology care in crisis settings. Findings reveal systemic neglect of cancer services due to disrupted infrastructure, legal barriers, and fragmented policy frameworks. Vulnerable groups - women, children, and the elderly - experience the greatest inequities. Ethical dilemmas in triage, limited palliative care, and inadequate digital connectivity further hinder equitable access. Emerging solutions include bilateral treatment agreements, WHO-led humanitarian oncology corridors, and tele-oncology or mobile unit models that sustain care across borders. Addressing cancer in humanitarian contexts is not merely a technical challenge but a moral imperative. Integrating oncology into emergency response protocols and global health governance is essential to ensure continuity, dignity, and justice in care for displaced and conflict-affected populations.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"139-155"},"PeriodicalIF":0.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic dysregulation and biological function of PDX1 in prostate cancer.","authors":"Tayo A Adeyika, Anju Datturgi, Yehnara Ettinoffe, Somiranjan Ghosh, Christopher Albanese, Bernard Kwabi-Addo","doi":"10.18632/oncotarget.28854","DOIUrl":"10.18632/oncotarget.28854","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Adeyika et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Aberrant DNA methylation changes lead to abnormal gene expression that contributes to the development and progression of prostate cancer (PCa). Inquiry of genome-wide DNA methylation dataset, we identified the homeodomain pancreatic and duodenal homeobox 1 (PDX1) gene as differentially hypermethylated in PCa compared to normal prostate tissues. Immunohistochemical analysis of matched PCa and normal prostate tissues using tissue microarray showed a significant 2.33-fold (p = 0.0001) higher PDX1 protein expression in the PCa compared to the normal prostate tissues. In PCa cell lines (PC-3 and LNCaP) engineered to stably overexpress or knockdown PDX1, the ectopic PDX1 expression significantly enhanced cell proliferation and migration, whereas PDX1 knockdown suppressed these phenotypic processes. Quantitative RT-PCR and Western blot analysis demonstrated that PDX1 overexpression was associated with increased expression of key metabolic regulators; INSR, IGF1R, CXCR4, CDH2, TWIST1, and SNAI1, whereas there is decreased expression of ESR2, and TNF&#x03B1;. Conversely, PDX1 knockdown led to the opposite effect in expression profiles of these metabolites. Notably, these effects were more pronounced under high-glucose conditions compared to low-glucose environments. Overall, our findings suggest that PDX1 plays a tumor-promoting role in human PCa cells by influencing expression of metabolites in insulin, inflammatory, and epithelial-mesenchymal transition (EMT) signaling pathways. Given its potential role in metabolic regulation, full insights into the function of PDX1 in PCa could contribute to improved treatment and prevention strategies, particularly for men with PCa and comorbidities such as obesity and diabetes.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"157-172"},"PeriodicalIF":0.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses.","authors":"Kayode Ahmed, Juan E N X Fa X F Ez-R X Ed Os","doi":"10.18632/oncotarget.28851","DOIUrl":"10.18632/oncotarget.28851","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Ahmed and N&#x00FA;&#x00F1;ez-R&#x00ED;os. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Burgeoning technological and clinical advances have significantly reshaped glioma classification. To assess the evolution of these changes, we analyzed bibliometric data from Web of Science to explore patterns in the socio-clinical domains of glioma classification research. Using network analysis, we built a direct citation network linking articles to authors, focusing on citations. Main Path Analysis provided an overview of research evolution, Key Route Analysis identified influential papers, and K-core analysis revealed densely connected articles. The network comprised 46,204 nodes and 231,432 arcs, highlighting DNA methylation profiling&#x2019;s role in advancing molecular biomarker-based classification models. KRA emphasized advanced imaging and molecular techniques as key drivers, while K-core analysis identified articles cited at least 19 times. The findings indicate that the subset of articles focusing on glioma classification that incorporate social factors is relatively scarce in the analyzed data, in contrast to the prominence of epigenetic and imaging factors in the literature. Unlike previous studies that focused primarily on metrics such as the h-index, our approach identifies the limited but notable mention of social factors in glioma classification research, thereby highlighting a thematic gap. Through quantitative network analysis complemented by narrative interpretation, we uncovered patterns and substructures that offer deep insights into the evolving research landscape.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"90-118"},"PeriodicalIF":0.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.","authors":"Gonzalo Sequeira, Silvia I Vanzulli, Paola Rojas, Caroline Lamb, Lucas Colombo, Mar X Ed A May, Alfredo Molinolo, Claudia Lanari","doi":"10.18632/oncotarget.28842","DOIUrl":"10.18632/oncotarget.28842","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"137-138"},"PeriodicalIF":0.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions.","authors":"Fakeng Liu, Rui Jin, Xiuju Liu, Henry Huang, Scott C Wilkinson, Diansheng Zhong, Fadlo R Khuri, Haian Fu, Adam Marcus, Yulong He, Wei Zhou","doi":"10.18632/oncotarget.28843","DOIUrl":"10.18632/oncotarget.28843","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"136"},"PeriodicalIF":0.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis.","authors":"Lili Yang, Gongliang Guo, Liqun Sun, Chenhao Li, Haipeng Zhang","doi":"10.18632/oncotarget.28834","DOIUrl":"10.18632/oncotarget.28834","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"156"},"PeriodicalIF":0.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}